An aggregated analysis of hormonal factors and endometrial cancer risk by parity

Cancer

Volumn 119, Issue 7, 2013, Pages 1393-1401

  Schonfeld, Sara J ^a,b   Hartge, Patricia ^a   Pfeiffer, Ruth M ^a   Freedman, D Michal ^a   Greenlee, Robert T ^c   Linet, Martha S ^a   Park, Yikyung ^a   Schairer, Catherine ^a   Visvanathan, Kala ^b,d   Lacey Jr , James V ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MARSHFIELD CLINIC   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

endometrial cancer; hormone; nulliparity; obesity; oral contraceptives; reproductive history

Indexed keywords

HORMONE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BODY MASS; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; NULLIPARA; OBESITY; ORAL CONTRACEPTION; PARITY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION;

CONTRACEPTIVES, ORAL; ENDOMETRIAL NEOPLASMS; FEMALE; HORMONES; HUMANS; MIDDLE AGED; OBESITY; PARITY; RISK FACTORS;

EID: 84875382619     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27909     Document Type: Article

References (37)

1. Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010; 127: 442-451.
2. Karageorgi S, Hankinson SE, Kraft P, De Vivo I,. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer. 2010; 126: 208-216.
3. Pfeiffer RM, Mitani A, Landgren O, et al. Timing of births and endometrial cancer risk in Swedish women. Cancer Causes Control. 2009; 20: 1441-1149.
4. Henderson BE, Feigelson HS,. Hormonal carcinogenesis. Carcinogenesis. 2000; 21: 427-433.
5. Key TJ, Pike MC,. The dose-effect relationship between "unopposed" oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988; 57: 205-212.
6. Kim JJ, Chapman-Davis E,. Role of progesterone in endometrial cancer. Semin Reprod Med. 2010; 28: 81-90.
7. Kvale G, Heuch I, Nilssen S,. Reproductive factors and cancers of the breast and genital organs-are the different cancer sites similarly affected? Cancer Detect Prev. 1991; 15: 369-377.
8. Baird DD, Dunson DB,. Why is parity protective for uterine fibroids? Epidemiology. 2003; 14: 247-250.
9. Brinton LA, Westhoff CL, Scoccia B, et al. Causes of infertility as predictors of subsequent cancer risk. Epidemiology. 2005; 16: 500-507.
10. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012. [Accessed July 2012]
11. Dye JL,. Fertility of American Women, 2008. Current Population Reports. Washington, DC: US Census Bureau; 2010.
12. Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C,. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1724-1731.
13. Schatzkin A, Subar AF, Thompson FE, et al. Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol. 2001; 154: 1119-1125.
14. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21 (6 suppl): 273S-309S.
15. Sigurdson AJ, Doody MM, Rao RS, et al. Cancer incidence in the US radiologic technologists health study, 1983-1998. Cancer. 2003; 97: 3080-3309.
16. Schonfeld SJ, Pfeiffer RM, Lacey JV Jr, et al. Hormone-related risk factors and postmenopausal breast cancer among nulliparous versus parous women: an aggregated study. Am J Epidemiol. 2011; 173: 509-517.
17. Fritz AG,. International Classification of Diseases for Oncology: ICD-O. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
18. Beral V, Bull D, Reeves G,. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005; 365: 1543-1551.
19. Chang SC, Lacey JV Jr, Brinton LA, et al. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP Diet and Health Study. Cancer Epidemiol Biomarkers Prev. 2007; 16: 723-730.
20. Lacey JV Jr, Leitzmann MF, Chang SC, et al. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Cancer. 2007; 109: 1303-1311.
21. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG,. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010; 19: 3119-3130.
22. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1996; 275: 370-375.
23. Hersh AL, Stefanick ML, Stafford RS,. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004; 291: 47-53.
24. Britt K, Ashworth A, Smalley M,. Pregnancy and the risk of breast cancer. Endocr Relat Cancer. 2007; 14: 907-933.
25. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA. 1987; 257: 796-800.
26. Brinton LA, Hoover RN,. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol. 1993; 81: 265-271.
27. Levi F, La Vecchia C, Gulie C, et al. Oral contraceptives and the risk of endometrial cancer. Cancer Causes Control. 1991; 2: 99-103.
28. Rubin GL, Peterson HB, Lee NC, Maes EF, Wingo PA, Becker S,. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol. 1990; 162: 148-154.
29. Schouten LJ, Goldbohm RA, van den Brandt PA,. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst. 2004; 96: 1635-1638.
30. Stanford JL, Brinton LA, Berman ML, et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer. 1993; 54: 243-248.
31. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I,. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control. 1999; 10: 277-284.
32. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE,. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol. 2007; 165: 262-270.
33. Bokhman JV,. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15: 10-17.
34. Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol. 2010; 172: 1394-1403.
35. Razavi P, Pike MC, Horn-Ross PL, Templeman C, Bernstein L, Ursin G,. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19: 475-483.
36. Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E,. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer. 2011; 128: 1644-1651.
37. Phipps AI, Doherty JA, Voigt LF, et al. Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer. Cancer Causes Control. 2011; 22: 1639-1646.